Abstract: An improved system for initially positioning and for continuous or intermittent monitoring of the location of the distal end of a feeding tube in a patient's gastrointestinal tract and for selectively controlling a feeding device associated therewith by detecting and processing myoelectric signals unique to different areas of the gastrointestinal tract, such signals being detected by electrodes carried by the distal end of the feeding tube and transmitted by leads extending through the feeding tube to a monitor.

Abstract: New compounds, tiacumicins, are produced by a microorganism belonging to the genus Dactylosporangium. The compounds are effective Gram-positive antibiotics.

Abstract: The invention relates to novel solution and suspension aerosol formulations comprising LHRH analogs.

Abstract: A tubing connector adapted for peritoneal dialysis connections between tubing sets and containers of dialysate. The connection prevents inadvertent disengagement of tubing sets.

Abstract: An expedited process for the dispersion and neutralization of acid caseins in the manufacture of liquid caseinate that drastically reduces time and cost variables and allows for in-house production of caseinate. The process comprises the initial addition of a solubilizing agent (i.e. citrate) to an aqueous solution with a temperature of about 120.degree. F. to about 165.degree. F. prior to the addition of casein and a neutralizing agent. This process achieves a pH-perfect, soluble caseinate product in the form of a ready-to-use liquid or powdered caseinate.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl;A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene;n is 1-5;Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.

Abstract: A process for the preparation of enantiomerically homogeneous aminopyrrolidinyl naphthyridine carboxylic acids and quinolone carboxylic acids, and for the preparation of intermediates that are useful in the production of these carboxylic acids. The compounds are useful as anti-bacterials.

Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.

Abstract: The invention relates to novel aerosol formulations comprising LHRH analogs, a lipophilic counterion, solvent and propellant and, optionally, surfactant, valve lubricant, an antioxidant and flavor and fragrance.

Abstract: A reference electrode is disclosed for use in potentiometric analysis of ion activity in a solution.

Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; aryalkyl; OR.sub.8 or SR.sub.8 wherein R.sub.8 is hydrogen, loweralkyl or aminoalkyl; NR.sub.9 R.sub.10 wherein R.sub.9 and R.sub.10 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.11 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, carboxylic acid-substituted alkyl, alkoxycarbonylalkyl, aminoalkyl, N-protected aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (N-protected)-(alkyl)aminoalkyl, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic; R.sub.1 is loweralkyl, cycloalkylmethyl, benzyl, .alpha.-methylbenzyl, .alpha.,.alpha.

Abstract: A process for producing racemic or optically active compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alkyl or benzyl; and Z is amino or substituted amino. Also disclosed are intermediates useful in the process and methods for producing the intermediates.

Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; Or.sub.10 wherein R.sub.10 is hydrogen or loweralkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen and loweralkyl; or R.sub.13 --CO--B wherein B is NH, O, CH.sub.2, HNCH.sub.2 and R.sub.13 is loweralkyl, alkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, N-protected aminoalkyl, hydroxylated dialkylamino, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic, carboxyalkyl, or lower alkyl carboxyalkyl esters; W is N or CH: U,V may be the following combinations H,OH; OH,H; H,H; or when taken together as O represents a carbonyl with the provisos that if U,V.dbd.H,OH, then W=CH, and if U,V.dbd.O then W.dbd.N; R.sub.1 , R.sub.3 and R.sub.5 are loweralkyl or hydrophilic, lipophilic or aromatic amino acid side chains and may be the same or different; R.sub.2, R.sub.4, R.sub.7, R.sub.8 and R.sub.

Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is ##STR2## wherein B is thiomorpholino, morpholino, 4-sulfonylmorpholino, 3,4-dihydroxypyrrolidino, alkoxy or loweralkyl and C is NH or CH.sub.2 ; R.sub.1, R.sub.3 and R.sub.7 are independently selected from loweralkyl or lipophilic or aromatic amino acid side chains; R.sub.2, R.sub.4, and R.sub.6 are independently selected from hydrogen or loweralkyl; R.sub.5 is phenyl, isopropyl, cyclohexyl, 1,3-dioxan-2-yl; 1,3-dioxolan-2-yl, loweralkyl, 1,3-dithiolan-2-yl or 1,3-dithian-2-yl; X is hydrogen, loweralkyl or --CH.sub.2 OR.sub.8, wherein R.sub.8 is hydrogen, loweralkyl or alkaryl; and R.sub.9 is hydrogen, loweralkyl, hydroxy, hydroxyalkyl, difluoro, alkoxy, allyl, alkaryloxy or thioalkyl and pharmaceutically acceptable salts thereof.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;X is (1) oxygen, (2) sulfur, (3) SO.sub.2, or (4) NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkyl or (4) aroyl;A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 0-4;Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C.sub.1 to C.sub.12 arylalkyl, (14) C.sub.2 to C.sub.12 arylalkenyl, (15) C.sub.1 to C.sub.12 arylalkoxy, (16) C.sub.1 to C.sub.

Abstract: Compounds of the formula: ##STR1## wherein R1 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, or NR2R3, wherein R2 and R3 are independently selected from hydrogen, C1 to C4 alkyl and hydroxyl, but R2 and R3 are not simultaneously hydroxyl;X is oxygen, sulfur, CO2, or NR4, wherein R4 is hydrogen, C1 to C6 alkyl, C1 to C6 alkoyl or aroyl;A is selected from C1 to C6 alkylene and C2 to C6 alkenylene;Y is selected independently at each occurrence from hydrogen, halogen, hydroxy, cyano, nitro, halosubstituted alkyl, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C3 to C8 cycloalkyl, aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, C1 to C12 arylthicalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, or C1 to C12 arylthioalkoxy, wherein C12 alkyl, alkoxy, and halosubstituted alkyl; n is a number having the values 0-4; when n=0 then Y=hydrogen;and M is hydrogen, a pharmaceutically acceptable cation,

Abstract: Method and apparatus for generating centrifugal forces, including a plate rotatable about an axis, and at least one holding means mounted on the plate for rotation therewith, the holding means being adapted to receive an article to be subjected to centrifugal force and being rotatable relative to the plate member to permit the direction of centrifugal force acting on the article to be changed.

Abstract: A reagent system for determing the hemoglobin content of whole blood comprising an aqueous solution of polyvinylpyrrolidone of molecular weight from about 10,000 to about 360,000 at a pH greater than about 8.0 to denature hemoglobin in whole blood. A method is also provided wherein a blood sample is treted with an aqueous solution of polyvinylpyrrolidone of molecular weight from about 10,000 to about 360,000 at a basic pH sufficient to denature the hemoglobin present in the whole blood to form a stable product whereafter the absorbance of the stable product of the blood sample and polyvinylpyrrolidone of molecular weight from about 10,000 to about 360,000 polymer reagent system is measured at a wavelength of approximately 575 nm to determine the hemoglobin contentration.